Psyence Biomedical (Psyence Biomedical) Cash And Cash Equivalents

: $1.32 Mil (As of Mar. 2023)

View and export this data going back to 2024. Start your Free Trial

Psyence Biomedical's quarterly cash and cash equivalents declined from Mar. 2021 ($4.77 Mil) to Mar. 2022 ($1.73 Mil) but then stayed the same from Mar. 2022 ($1.73 Mil) to Mar. 2023 ($1.32 Mil).

Psyence Biomedical's annual cash and cash equivalents declined from Mar. 2021 ($4.77 Mil) to Mar. 2022 ($1.73 Mil) and declined from Mar. 2022 ($1.73 Mil) to Mar. 2023 ($1.32 Mil).

Psyence Biomedical Cash And Cash Equivalents Historical Data

The historical data trend for Psyence Biomedical's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Psyence Biomedical Annual Data

Trend

Mar21

Mar22

Mar23

Cash And Cash Equivalents

4.77

1.73

1.32

Psyence Biomedical Semi-Annual Data
	Mar21	Mar22	Mar23
Cash And Cash Equivalents	4.77	1.73	1.32

Psyence Biomedical Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Psyence Biomedical (NAS:PBM) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Psyence Biomedical Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Psyence Biomedical's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Psyence Biomedical (Psyence Biomedical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Psyence Biomedical Ltd (NAS:PBM) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

121 Richmond Street West, Penthouse Suite 1300, Toronto, ON, CAN, M5H 2K1

Website

https://www.psyence.com

Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed ISO22000 facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

Psyence Biomedical (Psyence Biomedical) Headlines

From GuruFocus

Thinking about buying stock in Psyence Biomedical, Micron Technology, Conservative Broadcast Media Journalism, Qualcomm, or Cibus?

By PRNewswire • 02-12-2024